Joshua J Van Veldhuizen

This inventor holds 17 USPTO granted patents and 2 published patent applications and 5 EPO patents, primarily in Pharmaceutical Inhibitors. Top assignee: Gilead Sciences, Inc.. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joshua J Van Veldhuizen. Retrieved from https://idiyas.com/inventor/joshua-j-van-veldhuizen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 13.7

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

17 out of 946

Gilead Sciences, Inc.

patents

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

SARS-CoV-2

Protease Inhibitors

6-Azabenzimidazole

Peptidylarginine Deiminases

Phosphatidylinositol 3-Kinase

Benzimidazole

Imadazopyridine

Carboximidamide Compounds

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410183 - Sars-cov2 main protease inhibitors (2025-09-09),

2. 12258346 - Substituted 6-azabenzimidazole compounds (2025-03-25),

3. 12240862 - Inhibitors of peptidylarginine deiminases (2025-03-04),

4. 12091420 - SARS-COV2 main protease inhibitors (2024-09-17),

5. 11976083 - Inhibitors of peptidylarginine deiminases (2024-05-07),

6. 11925631 - Substituted 6-azabenzimidazole compounds (2024-03-12),

7. 11897878 - Substituted 6-azabenzimidazole compounds (2024-02-13),

8. 11878965 - Inhibitors of peptidylarginine deiminases (2024-01-23),

9. 11203591 - Substituted 6-azabenzimidazole compounds (2021-12-21),

10. 11071730 - Substituted 6-azabenzimidazole compounds (2021-07-27),

11. 11021467 - Phosphatidylinositol 3-kinase inhibitors (2021-06-01),

12. 10479770 - Phosphatidylinositol 3-kinase inhibitors (2019-11-19),

13. 10221197 - Phosphatidylinositol 3-kinase inhibitors (2019-03-05),

14. 10214519 - Phosphatidylinositol 3-kinase inhibitors (2019-02-26),

15. 10092563 - Phosphatidylinositol 3-kinase inhibitors (2018-10-09),

Title: Innovations of Joshua J Van Veldhuizen

Introduction

Joshua J Van Veldhuizen is a prominent inventor based in Seattle, WA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating viral infections. With a total of 17 patents to his name, his work has had a substantial impact on medical research and treatment options.

Latest Patents

Among his latest patents is a focus on Sars-cov2 main protease inhibitors. This patent relates to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in treating viral infections, specifically coronaviridae infections. Another notable patent involves substituted 6-azabenzimidazole compounds. This patent discusses certain 6-azabenzimidazole compounds, their pharmaceutical compositions, and methods for making and using these compounds. These compounds may be utilized for the treatment or prevention of diseases modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, including HBV, HIV, cancer, and hyper-proliferative diseases.

Career Highlights

Joshua is currently employed at Gilead Sciences, Inc., where he continues to innovate and develop new pharmaceutical solutions. His extensive experience and expertise in the field have positioned him as a key player in the industry.

Collaborations

Throughout his career, Joshua has collaborated with notable colleagues, including Gary Bruce Phillips and Jennifer Alissa Loyer-Drew. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Joshua J Van Veldhuizen is a distinguished inventor whose work in pharmaceuticals has led to significant advancements in the treatment of viral infections. His contributions continue to shape the future of medical research and innovation.

Profile summary based on public USPTO records.